Table 2.

Data of 30-day survivors and non-survivors with VA-ECMO.

VA-ECMO	30-day survivors (n = 21)	30-day non-survivors (n = 18)	P values
Age (year)	65 (55–71)	62 (49–66)	0.367
Sex (female/male)	2/19	5/13
APACHE II score	27 (24–32)	36 (27–39)	0.020
SAVE score	−5 (−9–−1)	−10 (−15–−7)	0.003
ECMO free daysa	22 (17–26)	1 (0–13)	0.001
ICU free daysb	0 (0–15)	0	0.009
T1 (within 24 h)
EAA	0.38 (0.20–0.51)	0.29 (0.20–0.46)	0.319
WBC (k/μL)	12.2 (9.5–17.4)	12.1 (9.7–15.9)	0.988
Inotropic score	4.1 (0–20.7)	12.9 (1.9–19.4)	0.483
Lactate (mmol/L)	10.1 (3.4–13.5)	9.5 (7.7–13.1)	0.478
T2 (25–48 h)
EAA	0.38 (0.20–0.52)	0.38 (0.33–0.52)	0.660
WBC (k/μL)	12.1 (10.6–15.3)	12.8 (8.8–15.6)	0.885
Inotropic score	4.6 (0.7–11.5)	9.2 (3.3–18.8)	0.147
Lactate (mmol/L)	2.9 (1.7–4.5)	3.1 (2.0–4.4)	0.641
T3 (49–72 h)
EAA	0.31 (0.19–0.51)	0.49 (0.37–0.63)	0.024
WBC (k/μL)	12.3 (9.0–15.2)	10.4 (7.9–12.2)	0.128
Inotropic score	2.3 (0.0–8.1)	7.5 (1.1–13.9)	0.220
Lactate (mmol/L)	1.9 (1.4–3.0)	2.5 (1.8–5.3)	0.056
T4 (73–96 h)
EAA	0.41 (0.29–0.52)	0.49 (0.29–0.61)	0.391
WBC (k/μL)	10.1 (8.8–13.5)	11.3 (7.9–11.9)	0.977
Inotropic score	0.9 (0–7.9)	3.2 (0–15.4)	0.427
Lactate (mmol/L)	1.8 (1.2–2.5)	2.5 (1.4–4.0)	0.126

Data are presented as medians (interquartile ranges), numbers, and percentages as appropriate. Study time points (T1–T4) represent the time after ECMO initiation. APACHE II, Acute Physiology and Chronic Health Evaluation II; EAA, endotoxin activity assay; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; SAVE, Survival after Venoarterial ECMO; VA-ECMO, venoarterial ECMO; WBC, white blood cell.

^aECMO free days were defined as days free from ECMO support from ECMO initiation until day 30.

^bICU free days were defined as days bot in the ICU, between ECMO initiation and day 30.